Citations

Clear

4847 citation(s) found for "Tu, Eric".

Catheter Ablation of Atrial Fibrillation in U.S. Community Practice—Results From Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT‐AF)
Holmqvist, Fredrik , Simon, DaJuanicia N., Hong, Seok Jae , Kowey, Peter R. , Reiffel, James A. , Chang, Paul, Piccini, Jonathan P. , Investigators, the ORBIT‐AF, Steinberg, Benjamin A. , Naccarelli, Gerald V. , Gersh, Bernard J. , Peterson, Eric D. , Investigators, the ORBIT‐AF

Mayo Clinic

Journal of the American Heart Association | May 22, 2015 | Volume: 4 | Issue: 5 | Pages: No page available

10.1161/jaha.115.001901 | PMID 25999401 Get It

Background The characteristics of patients undergoing atrial fibrillation ( AF ) ablation and subsequent outcomes in community practice are not well described. Methods and Results Using the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation ( ORBIT ‐ AF ), we investigated the prevalence and impact of catheter ablation of AF . Among 9935 patients enrolled, 5.3% had previous AF ablation. Patients with AF ablation were significantly younger, more frequently male, and had less anemia, chronic obstructive pulmonary disease, and previous myocardial infarction (P<0.05 for all analyses) than those without previous catheter ablation of AF . Ablated patients were more likely to have a family history of AF , obstructive sleep apnea, paroxysmal AF , and moderate‐to‐severe symptoms (P<0.0001 for all analyses). Patients with previous ablation were more often in sinus rhythm on entry into the registry (52% vs. 32%; P<0.0001). Despite previous ablation, 46% in the ablation group were still on antiarrhythmic therapy. Oral anticoagulation was prescribed in 75% of those with previous ablation versus 76% in those without previous ablation (P=0.5). The adjusted risk of death (hazard ratio [ HR ], 0.78; 95% confidence interval [ CI ], 0.52 to 1.18; P=0.2) and cardiovascular ( CV ) hospitalization ( HR , 1.06; 95% CI , 0.90 to 1.26; P=0.5) were similar in both groups. Patients with incident AF ablation had higher risk of subsequent CV hospitalization than matched patients without incident ablation ( HR , 1.67; 95% CI , 1.24 to 2.26; P=0.0008). Conclusions In U.S. clinical practice, a minority of patients with AF are managed with catheter ablation. Subsequent to ablation, there were no significant differences in oral anticoagulation use or outcomes, including stroke/non–central nervous system embolism/transient ischemic attack or death. Clinical Trial Registration URL : http://www.clinicaltrials.gov . Unique identifier: NCT 01165710.
Lateralization of mesial temporal lobe epilepsy with chronic ambulatory electrocorticography
King‐Stephens, David , Mirro, Emily A. , Weber, Peter, Laxer, Kenneth D. , Ness, Paul C. Van, Salanova, Vicenta , Spencer, David , Heck, Christianne, Jobst, Barbara C. , Shields, Donald C. , Bergey, Gregory K. , Eisenschenk, Stephan, Rossi, Marvin A. , Sperling, Michael R. , Nair, Dileep , Gwinn, Ryder P. , Park, Yong D., Rutecki, Paul , Fountain, Nathan B. , Wharen, Robert E. , Miller, Ian , Barkley, Gregory L., Geller, Eric B., Berg, Michel J., Sadler, Toni, Sun, Felice T., Morrell, Martha J. , Cole, Andrew J , Goldman, Alica M. , Worrell, Gregory A. , Gross, Robert E. , Cole, Andrew J. , Hirsch, Lawrence J. , Edwards, Jonathan C. W. , Sperling, Michael R , Fountain, Nathan , Jobst, Barbara , Nair, Dileep R , Morrell, Martha J

Mayo Clinic

Epilepsia | May 19, 2015 | Volume: 56 | Issue: 6 | Pages: 959-967

10.1111/epi.13010 | PMID 25988840 Get It

Summary Objective Patients with suspected mesial temporal lobe ( MTL ) epilepsy typically undergo inpatient video–electroencephalography ( EEG ) monitoring with scalp and/or intracranial electrodes for 1 to 2 weeks to localize and lateralize the seizure focus or foci. Chronic ambulatory electrocorticography ( EC oG) in patients with MTL epilepsy may provide additional information about seizure lateralization. This analysis describes data obtained from chronic ambulatory EC oG in patients with suspected bilateral MTL epilepsy in order to assess the time required to determine the seizure lateralization and whether this information could influence treatment decisions. Methods Ambulatory EC oG was reviewed in patients with suspected bilateral MTL epilepsy who were among a larger cohort with intractable epilepsy participating in a randomized controlled trial of responsive neurostimulation. Subjects were implanted with bilateral MTL leads and a cranially implanted neurostimulator programmed to detect abnormal interictal and ictal EC oG activity. EC oG data stored by the neurostimulator were reviewed to determine the lateralization of electrographic seizures and the interval of time until independent bilateral MTL electrographic seizures were recorded. Results Eighty‐two subjects were implanted with bilateral MTL leads and followed for 4.7 years on average (median 4.9 years). Independent bilateral MTL electrographic seizures were recorded in 84%. The average time to record bilateral electrographic seizures in the ambulatory setting was 41.6 days (median 13 days, range 0–376 days). Sixteen percent had only unilateral electrographic seizures after an average of 4.6 years of recording. Significance About one third of the subjects implanted with bilateral MTL electrodes required >1 month of chronic ambulatory EC oG before the first contralateral MTL electrographic seizure was recorded. Some patients with suspected bilateral MTL seizures had only unilateral electrographic seizures. Chronic ambulatory EC oG in patients with suspected bilateral MTL seizures provides data in a naturalistic setting, may complement data from inpatient video‐ EEG monitoring, and can contribute to treatment decisions.
Biology‐Driven Gene‐Gene Interaction Analysis of Age‐Related Cataract in the eMERGE Network
Hall, Molly A. , Wallace, John R. , Lucas, Anastasia, Berg, Richard L. , Connolly, John J. , Crawford, Dana C. , Crosslin, David R. , Doheny, Kimberly F. , Haines, Jonathan L. , Harley, John B. , Jarvik, Gail P. , Kitchner, Terrie, Kuivaniemi, Helena , Larson, Eric B. , Tromp, Gerard , Vrabec, Tamara R. , Pendergrass, Sarah A. , McCarty, Catherine A. , Ritchie, Marylyn D. , de Andrade, Mariza, Verma, Shefali S. , Andrade, Mariza de , Carrell, David , Jarvik, Gail P , Connolly, John J

Mayo Clinic

Genetic Epidemiology | May 18, 2015 | Volume: 39 | Issue: 5 | Pages: 376-384

10.1002/gepi.21902 | PMID 25982363 Get It

ABSTRACTBioinformatics approaches to examine gene‐gene models provide a means to discover interactions between multiple genes that underlie complex disease. Extensive computational demands and adjusting for multiple testing make uncovering genetic interactions a challenge. Here, we address these issues using our knowledge‐driven filtering method, Biofilter, to identify putative single nucleotide polymorphism (SNP) interaction models for cataract susceptibility, thereby reducing the number of models for analysis. Models were evaluated in 3,377 European Americans (1,185 controls, 2,192 cases) from the Marshfield Clinic, a study site of the Electronic Medical Records and Genomics (eMERGE) Network, using logistic regression. All statistically significant models from the Marshfield Clinic were then evaluated in an independent dataset of 4,311 individuals (742 controls, 3,569 cases), using independent samples from additional study sites in the eMERGE Network: Mayo Clinic, Group Health/University of Washington, Vanderbilt University Medical Center, and Geisinger Health System. Eighty‐three SNP‐SNP models replicated in the independent dataset at likelihood ratio test P < 0.05. Among the most significant replicating models was rs12597188 (intron of CDH1)–rs11564445 (intron of CTNNB1). These genes are known to be involved in processes that include: cell‐to‐cell adhesion signaling, cell‐cell junction organization, and cell‐cell communication. Further Biofilter analysis of all replicating models revealed a number of common functions among the genes harboring the 83 replicating SNP‐SNP models, which included signal transduction and PI3K‐Akt signaling pathway. These findings demonstrate the utility of Biofilter as a biology‐driven method, applicable for any genome‐wide association study dataset.
Do solar cycles influence giant cell arteritis and rheumatoid arthritis incidence?
Rider, Lisa G. , Johnson, J. R. , Miller, Frederick W. , Matteson, Eric L. , Crowson, Cynthia S. , Gabriel, Sherine E., Crowson, CS , Wing, Simon

Mayo Clinic

BMJ Open | May 15, 2015 | Volume: 5 | Issue: 5 | Pages: e006636

10.1136/bmjopen-2014-006636 | PMID 25979866 Get It

Objective To examine the influence of solar cycle and geomagnetic effects on the incidence of giant cell arteritis (GCA) and rheumatoid arthritis (RA). Methods We used data from patients with GCA (1950–2004) and RA (1955–2007) obtained from population-based cohorts. Yearly trends in age-adjusted and sex-adjusted incidence were correlated with the F10.7 index (solar radiation at 10.7 cm wavelength, a proxy for the solar extreme ultraviolet radiation) and AL index (a proxy for the westward auroral electrojet and a measure of geomagnetic activity). Fourier analysis was performed on AL, F10.7, and GCA and RA incidence rates. Results The correlation of GCA incidence with AL is highly significant: GCA incidence peaks 0–1 year after the AL reaches its minimum (ie, auroral electrojet reaches a maximum). The correlation of RA incidence with AL is also highly significant. RA incidence rates are lowest 5–7 years after AL reaches maximum. AL, GCA and RA incidence power spectra are similar: they have a main peak (periodicity) at about 10 years and a minor peak at 4–5 years. However, the RA incidence power spectrum main peak is broader (8–11 years), which partly explains the lower correlation between RA onset and AL. The auroral electrojets may be linked to the decline of RA incidence more strongly than the onset of RA. The incidences of RA and GCA are aligned in geomagnetic latitude. Conclusions AL and the incidences of GCA and RA all have a major periodicity of about 10 years and a secondary periodicity at 4–5 years. Geomagnetic activity may explain the temporal and spatial variations, including east-west skewness in geographic coordinates, in GCA and RA incidence, although the mechanism is unknown. The link with solar, geospace and atmospheric parameters need to be investigated. These novel findings warrant examination in other populations and with other autoimmune diseases.
ACR Appropriateness Criteria ® Metastatic Epidural Spinal Cord Compression and Recurrent Spinal Metastasis
Metastases:, Expert Panel on Radiation Oncology–Bone, Lo, Simon S. , Ryu, Samuel , Chang, Eric L. , Galanopoulos, Nicholas, Kim, Edward Y. , Kubicky, Charlotte Dai, Lee, Charles P., Rose, Peter S. , Sahgal, Arjun , Sloan, Andrew E. , Traughber, Bryan , Poznak, Catherine Van , Vassil, Andrew D. , Metastases:, Expert Panel on Radiation Oncology–Bone, Jones, Joshua , Teh, Bin Sing

Mayo Clinic

Journal of Palliative Medicine | May 14, 2015 | Volume: 18 | Issue: 7 | Pages: 573-584

10.1089/jpm.2015.28999.sml | PMID 25974663 Get It

Abstract Metastatic epidural spinal cord compression (MESCC) is an oncologic emergency and if left untreated, permanent paralysis will ensue. The treatment of MESCC is governed by disease, patient, and treatment factors. Patient's preferences and goals of care are to be weighed into the treatment plan. Ideally, a patient with MESCC is evaluated by an interdisciplinary team promptly to determine the urgency of the clinical scenario. Treatment recommendations must take into consideration the risk-benefit profiles of surgical intervention and radiotherapy for the particular individual's circumstance, including neurologic status, performance status, extent of epidural disease, stability of the spine, extra-spinal disease status, and life expectancy. In patients with high spinal instability neoplastic score (SINS) or retropulsion of bone fragments in the spinal canal, surgical intervention should be strongly considered. The rate of development of motor deficits from spinal cord compression may be a prognostic factor for ultimate functional outcome, and should be taken into account when a treatment recommendation is made. The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed every three years by a multidisciplinary expert panel. The guideline development and review include an extensive analysis of current medical literature from peer-reviewed journals and the application of a well-established consensus methodology (modified Delphi) to rate the appropriateness of imaging and treatment procedures by the panel. In those instances where evidence is lacking or not definitive, expert opinion may be used to recommend imaging or treatment.
Endoscopic Ultrasound Fine-Needle Aspiration Cytology Mutation Profiling Using Targeted Next-Generation Sequencing
Gleeson, Ferga C. , Kipp, Benjamin R. , Voss, Jesse S. , Campion, Michael B., Minot, Douglas M., Tu, Zheng Jin, Klee, Eric W. , Sciallis, Andrew P. , Graham, Rondell P. , Henry, Michael , Levy, Michael J., Lazaridis, Konstantinos N. , Levy, Michael J. , Graham, Rondell P

Mayo Clinic

American Journal of Clinical Pathology | May 13, 2015 | Volume: 143 | Issue: 6 | Pages: 879-888

10.1309/ajcpu3j7fgayqbrl | PMID 25972331 Get It

TERT gene harbors multiple variants associated with pancreatic cancer susceptibility
Campa, Daniele , Rizzato, Cosmeri , Pacetti, Paola, Vodička, Pavel , Cleary, Sean P. , Capurso, Gabriele , Bueno‐de‐Mesquita, H. Bas, Werner, Jens , Butterbach, Katja, Ivanauskas, Audrius , Giese, Nathalia A. , Petersen, Gloria M. , Fogar, Paola, Bassi, Claudio , Ryska, Miroslav , Theodoropoulos, George , Li, Donghui , Greenhalf, William , Pasquali, Claudio , Hackert, Thilo , Fuchs, Charles S. , Mohelníková-Duchoňová, Beatrice , Funel, Niccola , Dieffenbach, Aida Karina, Buring, Julie E. , Holcátová, Ivana , Costello, Eithne , Zambon, Carlo‐Federico , Kupčinskas, Juozas , Bracci, Paige M. , Pezzilli, Raffaele , Olson, Sara H. , Sesso, Howard D. , Hartge, Patricia, Strobel, Oliver , Małecka‐Panas, Ewa , Visvanathan, Kala , Arslan, Alan A. , Pedrazzoli, Sergio , Souček, Pavel , Gioffreda, Domenica , Talar‐Wojnarowska, Renata , Scarpa, Aldo , Mambrini, Andrea , Jacobs, Eric J. , Jamroziak, Krzysztof , Tavano, Francesca , Bambi, Franco , Landi, Stefano , Austin, Melissa A. , Vodičková, Ludmila, Brenner, Hermann , Fave, Gianfranco Delle, Piepoli, Ada, Cantore, Maurizio , Zheng, Wei , Wolpin, Brian M. , Ámundadóttir, Laufey T. , Canzian, Federico , Wang, Zhaoming , Salvia, Roberto , Stolzenberg‐Solomon, Rachael Z. , Gazouli, Maria , Wang, Zhaoming , Kooperberg, Charles , Sperti, Cosimo , Wareham, Nicholas J. , Kupcinskas, Juozas , Risch, Harvey A. , Kraft, Peter , Key, Tim , Klein, Alison P. , Chanock, Stephen Jacob , Amundadottir, Laufey , Arslan, Alan A , Canzian, Federico , Wang, Zhaoming , Visvanathan, Kala , Brenner, Hermann , Strobel, Oliver , Zheng, Wei , Cleary, Sean P , Vodicka, Pavel , Landi, Stefano , Holcatova, Ivana , Tavano, Francesca

Mayo Clinic

International Journal of Cancer | May 5, 2015 | Volume: 137 | Issue: 9 | Pages: 2175-2183

10.1002/ijc.29590 | PMID 25940397 Get It

A small number of common susceptibility loci have been identified for pancreatic cancer, one of which is marked by rs401681 in the TERT–CLPTM1L gene region on chromosome 5p15.33. Because this region is characterized by low linkage disequilibrium, we sought to identify whether additional single nucleotide polymorphisms (SNPs) could be related to pancreatic cancer risk, independently of rs401681. We performed an in‐depth analysis of genetic variability of the telomerase reverse transcriptase (TERT) and the telomerase RNA component (TERC) genes, in 5,550 subjects with pancreatic cancer and 7,585 controls from the PANcreatic Disease ReseArch (PANDoRA) and the PanScan consortia. We identified a significant association between a variant in TERT and pancreatic cancer risk (rs2853677, odds ratio = 0.85; 95% confidence interval = 0.80–0.90, p = 8.3 × 10−8). Additional analysis adjusting rs2853677 for rs401681 indicated that the two SNPs are independently associated with pancreatic cancer risk, as suggested by the low linkage disequilibrium between them (r2 = 0.07, D′ = 0.28). Three additional SNPs in TERT reached statistical significance after correction for multiple testing: rs2736100 (p = 3.0 × 10−5), rs4583925 (p = 4.0 × 10−5) and rs2735948 (p = 5.0 × 10−5). In conclusion, we confirmed that the TERT locus is associated with pancreatic cancer risk, possibly through several independent variants.
Abstract 5592: Molecular classification of triple negative breast cancer via RNA-sequencing data
Sun, Zhifu, Sicotte, Hugues , Vedell, Peter T. , Barman, Poulami , Passow, Jeanette E. Eckel, Wieben, Eric D. , Wang, Liewei , Weinshilboum, Richard, Thompson, Kevin J. , Tang, Xiaojia , Sinnwell, Jason P. , Mahoney, Douglas W. , Hart, Steven N. , Ingle, James N. , Boughey, Judy C. , Kalari, Krishna R. , Goetz, Matthew P.

Mayo Clinic

Cancer Research | May 4, 2015 | Volume: 74 | Issue: 19_Supplement | Pages: 5592-5592

10.1158/1538-7445.am2014-5592 Get It

Abstract Introduction: Triple negative breast cancers (TNBC) are characterized as lacking estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) expression and TNBC patients have higher rates of recurrence and death compared with other breast cancer subtypes. For TNBC patients who fail standard chemotherapy, there are a lack of novel drug therapies, given the absence of well-defined molecular targets. Recently, a microarray meta-analysis identified 7 triple negative subtypes, including the validation of the luminal androgen receptor (LAR) positive subtype [Lehmann, 2011]. However, microarray technology is dependent on probe-target specificity and the 7 subtypes have yet to be validated using RNA sequencing data, and the presences of recurrent genomic alterations in the 7 subtypes are unknown. METHODS: We obtained 1106 breast cancer RNA-Seq bam files from The Cancer Genome Atlas (TCGA) and aligned with Tophat v1.3. The PAM50 intrinsic gene signature was used to extract a cohort of 128 TNBC samples. Consensus clustering of genes, greater than 75th percentile of variance, was performed using Kmeans clustering in Spearman's correlation space. A nearest centroid prediction model was developed from genes differentially expressed among the clusters. Eighty independent TNBC RNA sequencing samples were obtained (British Colombia; BC) [Shah, 2012] which were calibrated to our TNBC conditional quantile normalized cohort and sub-typed by our model. RESULTS: Using RNA-Seq gene expression count data, we identified 5 clusters, all of which were stable, including the LAR cluster. Signaling pathway impact analysis (SPIA) implicated cytokine-cytokine receptor interaction, leukocyte transendothelial migration, and regulation of actin cytoskeleton pathways commonly altered in the non-LAR TNBC subtypes. In contrast, cell cycle, ECM-receptor interaction, endocrine regulated calcium reabsorption, and insulin signaling pathways were altered in the LAR versus non-LAR subtypes. Neuroactive ligand-receptor interactions were observed to be altered commonly between all sub-types. We then applied our model to the Shah, et al cohort. In this cohort, the LAR subtype was consistent with Shah's classification of ‘other’ TNBC and contained no basal samples by PAM50 intrinsic modeling. Analysis of sub-type specific mutation data from the BC cohort demonstrates an increased mutational load in ECM-related proteins, particularly the myosins, along with increased TP53 clonality in the non-LAR subtypes. CONCLUSIONS: Using TCGA RNASeq data, we have confirmed the presence of 5 major TNBC subtypes, including the LAR; which was negligible in basal composition by PAM50 intrinsic modeling. SPIA pathway analysis indicates a core set of pathways demonstrating altered expression across the TNBC sub-types and the identification of molecular targets within each subtype is ongoing. Citation Format: Kevin J. Thompson, Xiaojia Tang, Zhifu Sun, Jason P. Sinnwell, Hugues Sicotte, Douglas W. Mahoney, Steven Hart, Peter T. Vedell, Poulami Barman, Jeanette E. Eckel Passow, Eric D. Wieben, James N. Ingle, Judy C. Boughey, Liewei Wang, Richard Weinshilboum, Krishna R. Kalari, Matthew P. Goetz. Molecular classification of triple negative breast cancer via RNA-sequencing data. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 5592. doi:10.1158/1538-7445.AM2014-5592
Abstract 5078: Genome wide association study identifies variants at 16p13 associated with survival in multiple myeloma patients
Déan, Eric, Serie, Daniel, Campa, Daniele , Bracci, Paige M. , Buda, Gabriele , Dudziński, Marek , Greenberg, Alexandra J. , Hunstman, Scott, Jamroziak, Krzysztof , Kumar, Shaji , Martin, Thomas G. , Martínez‐López, Joaquín , Wolf, Jeffrey L. , Vachon, Celine M. , Martinez-Lopez, Joaquin , Ziv, Elad , Hu, Donglei , Martino, Alessandro Di , Aftab, Blake T. , Caswell‐Jin, Jennifer L. , Dumontet, Charles , Fejerman, Laura , Jurczyszyn, Artur , Marques, Herlander , Rajkumar, S. Vincent , Sáinz, Juan , Vangsted, Annette Juul , Wątek, Marzena , Slager, Susan L. , Canzian, Federico , Vachon, Celine M. , Martinez-Lopez, Joaquin , Martinez-Lopez, Joaquin

Mayo Clinic

Cancer Research | May 4, 2015 | Volume: 74 | Issue: 19_Supplement | Pages: 5078-5078

10.1158/1538-7445.am2014-5078 Get It

Abstract Background: Genome wide association studies (GWAS) have recently identified 8 loci identified with multiple myeloma (MM) susceptibility. We hypothesized that germ line genetic variants may also affect MM progression. We performed the first GWAS of MM survival, by conducting a meta-analysis of two existing studies at University of California San Francisco (UCSF) and the Mayo Clinic, and replicating findings in the International Multiple Myeloma rESEarch (IMMEnSE) consortium. Methods: The UCSF study included 353 MM patients genotyped on an Illumina Omni5 and Illumina 660 array. The Mayo clinic study included 239 MM patients genotyped on an Affymetrix 6.0 array. We imputed missing genotypes using the 1000 Genomes dataset and performed a GWAS for survival using proportional hazards models adjusting for age and gender and genetic ancestry using principal components analysis. We conducted a meta-analysis of the results from the two GWAS. We replicated the top SNPs in the IMMEnSE cohort which included 772 patients with survival data from 7 European countries and one North American site. We used the dataset from Grundberg et al (Nat Genetics 2012) to test for an association between SNPs associated with survival and gene expression in immortalized lymphocytes. We used gene expression data from Zhan et al (Blood 2006) to analyze the association between expression and survival. Results: In meta-analysis, we found a genome wide significant association between SNPs on a region at 16p13 and survival (rs72773978; p=2.9x10e-10). Patients with the minor allele were at increased risk for mortality (HR 2.73; 95% CI: 1.99 - 3.73). The top associated SNPs were all in strong linkage disequilibrium and were centered over the gene FOPNL. We replicated the association in the IMMEnSE cohort and found a significant association between the top SNP from the discovery dataset (rs72773978 p=0.037). We used previously published data to determine the association between gene expression and the top associated SNPs from the GWAS. The top SNP (rs72773978) was not in previously published eQTL databases, so we used rs7201759 which was also associated with survival in our data (p=3.8x10e-10) as a proxy. The minor allele for this SNP was associated with increased levels of expression of FOPNL (p=9x10e-5), but not with expression of any other genes within a 1 megabase region. Finally, we also observed an association between increased expression of FOPNL and shorter survival (HR: 2.62 per standard deviation.; 95% CI: 1.08 - 6.32). Conclusion: Germ line variants at 16p13 near the FOPNL gene are associated with survival among MM patients. FOPNL is thought to be involved in centrosomal function, and centrosomal activity has previously been associated with survival in MM patients. Our results support this previous observation. Furthermore, they suggest that germ line variants could also be useful in assessing prognosis for patients with MM. Citation Format: Elad Ziv, Eric Dean, Donglei Hu, Alessandro Martino, Daniel Serie, Daniele Campa, Blake Aftab, Paige Bracci, Gabriele Buda, Jennifer Caswell, Charles Dumontet, Marek Dudziński, Laura Fejerman, Alexandra Greenberg, Scott Hunstman, Artur Jurczyszyn, Krzysztof Jamroziak, Shaji Kumar, Herlander Marques, Thomas Martin, Joaquin Martinez-Lopez, Vincent Rajkumar, Juan Sainz, Annette Juul Vangsted, Marzena Watek, Jeffrey Wolf, Susan Slager, Federico Canzian, Celine Vachon. Genome wide association study identifies variants at 16p13 associated with survival in multiple myeloma patients. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 5078. doi:10.1158/1538-7445.AM2014-5078
Abstract 4185: Analysis of sequencing data to identify potential drug targets for an individual newly diagnosed with basal breast cancer who failed to respond to current standard neoadjuvant chemotherapy
Barman, Poulami , Sicotte, Hugues , Vedell, Peter T. , Dockter, Travis , Jones, Katie N., Conners, Amy Lynn , Moyer, Ann M. , Visscher, Daniel W., Gao, Bowen , McLaughlin, Sarah A., Copland, John A. , Moreno‐Aspitia, Alvaro , Northfelt, Donald W. , Gray, Richard J. , Passow, Jeanette E. Eckel, Kocher, Jean‐Pierre , Wieben, Eric D. , Farrugia, Gianrico , Schultz, Cloann G. , Weinshilboum, Richard, Wang, Liewei , Kalari, Krishna R. , Tang, Xiaojia , Thompson, Kevin J. , Mahoney, Douglas W. , Sinnwell, Jason P. , Hart, Steven N. , Yu, Jia Xin , Suman, Vera J. , Ingle, James N. , Goetz, Matthew P. , Boughey, Judy C.

Mayo Clinic

Cancer Research | May 4, 2015 | Volume: 74 | Issue: 19_Supplement | Pages: 4185-4185

10.1158/1538-7445.am2014-4185 Get It

Abstract INTRODUCTION Next generation sequencing (NGS) of patients has significantly changed our ways to study cancer genomics as it provides precise estimates of gene expression, fusion transcripts, expressed single nucleotide variants (eSNVs), splice variants and copy number variants. The Breast Cancer Genome Guided Therapy (BEAUTY) is an ongoing clinical study in which RNA sequencing (RNAseq) and whole exome sequencing (WES) are performed prior to, during and after neoadjuvant chemotherapy. Here we report the use of these sequencing technologies to investigate gene expression levels and mutational profiles in a triple negative breast cancer (TNBC) patient enrolled in BEAUTY whose disease did not respond to neoadjuvant paclitaxel and anthracycline/cycphosphamide. METHODS Computational approaches were used to integrate WES and RNAseq data obtained before therapy (V1T), after 12 weekly paclitaxel treatments (V2T) and after anthracycline-based regimen at surgical resection (V3T) to study a single patient with persistent TNBC disease after neoadjuvant chemotherapy. RESULTS Using RNA-Seq data, we identified an inter-chromosomal fusion transcript between chromosome 20 and 22 (GNAS-TTC38) that was highly expressed at V1T, V2T and V3T. We also identified intra-chromosomal fusion transcripts that were expressed at two time points, such as fusion transcript (KANSL1-ARL17A) on chromosome 17 for V1T and V2T and fusion transcript (RBM12B-LINC00535) on chromosome 8 for V2T and V3T time points. Several gene expression changes were also observed. Gene expression analysis of V1T, V2T and V3T tumors was performed. Differential temporal gene expression profiles of 9884 genes that were significant and varying at different time points were obtained for pathway analysis. Pathway analysis of 9884 genes identified up regulation and down regulation of several transcription factors with a fold change of 2x or more. When compared to blood, DNA tumor and RNA-Seq data, we identified 81 common somatic eSNVs that were expressed in both V1T and V2T time points and we are in the process of investigating V3T data. We found alterations of key transporter domains (CD225, Coatamer_beta_C, DUF2435, Dynamitin, EI24, GLTP, LMF1, Porin_3, V-ATPase_C) in our V1T and V2T SNV data. Similar to gene expression analysis, we are in the process of obtaining the list of mutations at various time points to identify driver and passenger mutation candidate genes for this specific TNBC patient. CONCLUSIONS Our initial time-series analysis of eSNV, fusion transcripts and gene expression data demonstrate that intensive analysis for individual patients is feasible. Further investigation of drug transporters and transcription regulators may help develop personalized treatment strategies for patients with disease resistant to current regimens. Citation Format: Krishna R. Kalari, Xiaojia Tang, Kevin J. Thompson, Douglas W. Mahoney, Poulami Barman, Jason P. Sinnwell, Hugues Sicotte, Peter Vedell, Steven N. Hart, Travis J. Dockter, Katie N. Jones, Amy L. Conners, Ann M. Moyer, Daniel W. Visscher, Jia Yu, Bowen Gao, Sarah A. McLaughlin, John A. Copland, Alvaro Moreno-Aspitia, Donald W. Northfelt, Richard J. Gray, Vera J. Suman, Jeanette E. Eckel Passow, Jean-Pierre A. Kocher, Eric D. Wieben, Gianrico Farrugia, Cloann G. Schultz, James N. Ingle, Richard Weinshilboum, Matthew P. Goetz, Liewei Wang, Judy C. Boughey. Analysis of sequencing data to identify potential drug targets for an individual newly diagnosed with basal breast cancer who failed to respond to current standard neoadjuvant chemotherapy. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 4185. doi:10.1158/1538-7445.AM2014-4185